Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (P50 Clinical Trial Optional)
ID: 357959Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Award Range

$0 - $150K

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/357959

Additional Information

http://grants.nih.gov/grants/guide/rfa-files/RFA-CA-25-007.html
Timeline
    Description

    The National Institutes of Health (NIH) has announced a funding opportunity titled "Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research," aimed at encouraging revision applications from currently funded NCI P50 specialized centers. This initiative seeks to expand existing research by integrating new technologies developed through the NCI Innovative Molecular Analysis Technologies (IMAT) program, promoting interdisciplinary collaboration to enhance cancer research effectiveness and validation of these technologies. The funding, estimated at $150,000 per award with a total of three awards available, is intended to support projects that aim to reduce cancer risks, improve screening and diagnostic methods, and advance cancer treatments. Applications are due by 5:00 PM local time on October 3, 2025, and interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    RFA-CA-25-007-Full-Announcement.html
    RFA-CA-25-007.html
    The National Cancer Institute (NCI), part of the Department of Health and Human Services, has issued a Notice of Funding Opportunity (NOFO) aimed at encouraging revision applications from currently funded NCI P50 specialized centers. The funding opportunity, titled "Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research," invites applicants to expand on existing research by integrating new technologies developed through the NCI Innovative Molecular Analysis Technologies (IMAT) program. The initiative seeks to promote interdisciplinary collaboration to enhance cancer research effectiveness and validation of these technologies. The funding goal is to reduce cancer risks, improve screening and diagnostic methods, foster advancements in cancer treatments, and enrich the quality of life for survivors. The estimated funding for fiscal year 2026 allocates $700,000 for about three awards. Eligible organizations include higher education institutions, nonprofits, state and local governments, and foreign entities. Applications are due by 5:00 PM local time on specified dates, with a strong emphasis on compliance with all application guidelines to ensure acceptance for review. This competitive grant will undergo a rigorous peer review process based on scientific and technical merit, relevance, and alignment with program priorities.
    Similar Opportunities
    Revision Applications for Validation of Biomarker Assays Developed Through NIH-Supported Research Grants (R01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a Notice of Funding Opportunity (NOFO) for revision applications aimed at validating biomarker assays developed through NIH-supported research grants, specifically under the R01 mechanism, with a focus on enhancing their clinical application for cancer detection and treatment. This initiative seeks to accelerate the translation of molecular, cellular, and imaging markers into clinical settings, encouraging multidisciplinary collaborations among scientists, clinicians, and laboratory experts to adapt and validate these biomarkers for various cancer-related purposes. Eligible applicants include a wide range of organizations such as higher education institutions, nonprofits, and tribal governments, with funding available up to $150,000 for a project period of up to three years. Interested parties should note that the application deadline is October 13, 2026, and can find further details and guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov.
    Revision Applications for Validation of Biomarker Assays Developed Through NIH-Supported Research Grants (R01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Revision Applications for Validation of Biomarker Assays Developed Through NIH-Supported Research Grants," aimed at accelerating the clinical validation of biomarker assays for cancer detection, diagnosis, prognosis, and treatment response. This initiative encourages multidisciplinary collaboration among researchers, clinicians, and statisticians, focusing on assays that have nearly completed analytical validation and utilize human specimens. The funding amount is capped at $150,000 per year for a maximum duration of three years, with application deadlines starting from January 14, 2025, and concluding on October 15, 2026. Interested applicants can find more information and guidelines at the NIH Grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a grant opportunity titled "Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)." This funding aims to support innovative projects that develop technologies for analyzing and managing biospecimens in cancer research and clinical care, with a focus on proof-of-concept studies that demonstrate feasibility in areas such as cancer biology, early detection, and health disparities. The total estimated program funding is $4.7 million, with individual awards ranging from $50,000 to $150,000, and approximately 17 awards are expected to be made. Interested applicants can reach out to Dr. Kelly Crotty at Kelly.crotty@nih.gov or by phone at 240-255-0917 for further information, with applications due by April 10, 2026.
    Integration of Imaging and Fluid-Based Tumor Monitoring in Cancer Therapy (R01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Cancer Institute (NCI), is offering a funding opportunity for R01 grant applications focused on the integration of imaging and fluid-based tumor monitoring in cancer therapy. The objective is to enhance research designs that utilize imaging and liquid biopsy assays to assess treatment responses and the emergence of resistance in cancer patients, thereby advancing precision medicine in cancer treatment. This initiative is critical for improving diagnostic techniques and patient monitoring strategies across various cancer types. Eligible applicants, including universities, for-profit organizations, and nonprofits, can apply for grants with a maximum budget of $500,000 per year for projects lasting up to five years. Applications will be accepted from January 5, 2025, until January 8, 2028, and interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Toward Translation of Nanotechnology Cancer Interventions (TTNCI; R01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Toward Translation of Nanotechnology Cancer Interventions" (TTNCI), aimed at supporting advanced pre-clinical research in nanotechnology-based cancer diagnostics and therapeutics. This initiative encourages innovative projects that utilize nanoparticle formulations or nano-devices to address significant clinical objectives in cancer treatment, with a focus on enhancing treatment efficacy through combination therapies and immunotherapy. Funding is available up to $475,000 annually for a maximum of four years, with applications accepted from eligible institutions including higher education entities, nonprofits, and government organizations. Interested applicants should refer to the detailed application process outlined on Grants.gov and the NIH ASSIST system, with key deadlines spanning from April 2025 to November 2027. For further inquiries, contact NIH Grants Information at grantsinfo@nih.gov.
    Forecast to Publish a Funding Opportunity Announcement for Sustained Support for Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is preparing to publish a Notice of Funding Opportunity (NOFO) aimed at supporting the sustained development of informatics technologies for cancer research and management. This initiative seeks applications for the continued operation and enhancement of existing informatics resources that facilitate data acquisition, management, analysis, and dissemination across various aspects of cancer research, including biology, treatment, early detection, and health disparities. The emphasis is on maintaining resources that have demonstrated significant impact on cancer research, with a focus on user engagement and support. While applications are not currently being solicited, potential applicants are encouraged to prepare collaborative projects in anticipation of the NOFO, which is expected to be posted on August 29, 2025, with a closing date for submissions on November 21, 2025. For further inquiries, interested parties can contact Dr. Juli Klemm at juli.klemm@gmail.com or by phone at 202-853-7889.
    Innovative Research in Cancer Nanotechnology (IRCN; R01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Innovative Research in Cancer Nanotechnology (IRCN; R01 Clinical Trial Not Allowed)" aimed at advancing research in cancer biology and oncology through the application of nanotechnology. This initiative encourages proposals that address significant challenges in these fields by focusing on mechanistic studies of nanomaterial interactions with biological systems, rather than clinical applications. The program is particularly important for enhancing the understanding of nanoparticle delivery mechanisms and improving diagnostic technologies in cancer treatment. Interested applicants can apply for grants with a budget cap of $475,000 per year over a maximum project period of five years, with applications due by May 5, 2026. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage at https://grants.nih.gov/grants/guide/pa-files/PAR-23-246.html.
    Forecast to Publish a Funding Opportunity Announcement for Advanced Development of Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is preparing to publish a Notice of Funding Opportunity (NOFO) aimed at advancing the development of informatics technologies for cancer research and management. This initiative seeks applications for the enhancement of emerging informatics technologies that have shown potential in improving data acquisition, analysis, visualization, and interpretation across various aspects of cancer research, including biology, treatment, early detection, and health disparities. The emphasis is on technologies that are unique and have the potential for significant impact, with a requirement for clear development plans, user engagement, and collaboration strategies. While applications are not currently being solicited, interested parties are encouraged to prepare for submission, with the estimated synopsis post date set for August 29, 2025, and a projected award date of July 1, 2026. For further inquiries, potential applicants can contact Juli Klemm, PhD, at juli.klemm@nih.gov or by phone at 202-853-7889.
    NCI Small Grants Program for Cancer Research (NCI Omnibus) (R03 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced the NCI Small Grants Program for Cancer Research (R03), aimed at supporting short-term cancer research projects that require limited resources. This funding opportunity encourages diverse research efforts, including pilot studies, secondary data analyses, and the development of research methodologies, with a maximum budget of $50,000 per year for projects lasting up to two years. The program is designed to address significant knowledge gaps in cancer research and is open to a wide range of applicants, including public, private, and foreign entities. Interested parties should note that the application period opens on January 24, 2025, with a submission deadline of February 24, 2025. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    Forecast to Publish a Funding Opportunity Announcement for Early-Stage Development of Informatics Technologies for Cancer Research and Management (U01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is preparing to publish a Notice of Funding Opportunity (NOFO) aimed at soliciting applications for the early-stage development of informatics technologies that enhance cancer research and management. This initiative, part of the National Cancer Institute's Informatics Technology for Cancer Research (ITCR) Program, seeks to support the creation and significant modification of tools that facilitate data acquisition, management, analysis, and dissemination across various cancer research domains, including biology, treatment, early detection, and health disparities. Interested small businesses are encouraged to develop innovative, user-friendly technologies that demonstrate potential impact on cancer research, with applications expected to be submitted after the NOFO is officially released. For further inquiries, potential applicants can contact Dr. Juli Klemm at juli.klemm@nih.gov or by phone at 202-853-7889, with the estimated synopsis post date set for August 29, 2025, and the anticipated award date in July 2026.